Member Info for Krone

So my post of a few minutes ago has disappeared from my mobile?

Site down all day yesterday now showing Sar sp at 13.671 presumably site has been hacked or has the party started?

Wise words indeed!

In Tim's 2007? update he indicates his expectation that Sareum will enter into licencing or co-development deals in respect of Chk1, Aurora Flt3 and Tyk2 'by the end of the calendar year'. 11 years later we have 1 deal...... Perhaps the 'middle of this year' for the Tyk2 update should be taken with a large pinch of salt. www.youtube.com/watch?v=ymYWP9OfbWo

...’acquiring complementary businesses’. Tim and John wouldn’t sell out for c. $300 would they....surely not!

Many thanks that's encouraging - do you have access to the paper below which might throw further light on the extent of the 'competition': https://www.sciencedirect.com/science/article/pii/S1568997218301332 'The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials'

To what extent are BMS stealing a march on SLE given that they are commencing Phase 2 studies - https://lupusnewstoday.com/2018/05/04/collaboration-advances-phase-2-trial-testing-potential-therapy-lupus/

Nick Glover's apparent confidence and eloquence certainly inspires hope for successful outcomes....

It takes Parker to retweet Sierra’s tweet following presentation today.....

Agree entirely Thoth, there is absolutely no evidence that Parker has done anything significant other than regularly pontificate about Brexit and in so doing alienate many. It isn't the behaviour of a professional and while he has a right to his opinions, they represent a conflict of interest and should not in any way be linked to his involvement as chairman of Sareum. Tim and John are solely focussed on developing the molecules and don't appear to have the financial or commercial savvy, or time for that matter, required to market the targets which they have spent years developing. There seems to be a high risk that Sareum will miss the boat if we don't get the level of exposure and generate the interest that the targets clearly warrant. Tim and John would be well advised to consider Parker's on-going involvement. imo

Nonetheless positive indications for Sierra’s other target..... Encouraging readthrough to Sierra’s SRA141! TAK-931’s first in human study reported at #ASCO18. Cdc7 validated as cancer target with 3 Partial Responses, 4 prolonged Stable Disease and acceptable safety profile. SRA141 IND submission planned for H2 2018. ow.ly/VpMs30kjsMr

Thanks Thoth, so a c. 20 bagger then....worth waiting a bit longer for!

So what will pfizer pay for our molecule as is?

Anything likely to arise from this?

So what’s Sierra worth to Lilly or other big pharma in terms of buyout and what would the impact be on Sar?

Having re-listened to www.youtube.com/watch?v=26Gm1Gr96Rk Tim actuually talks about 'middle of the year' for the selection of a Tyk2 candidate for pre-clinical develeopment....

Correction...25 working days

...we should know the outcome of the Tyk2 candidate selection....what will that do to the SP?

Regarding the Tyk2 patent, John indicated in communication following the December AGM that we should expect a response within the next 12 months.

It is surely inconceivable that having entered into a multi million dollar licence agreement, Sareum don't know precisely what will trigger the milestone payments.